Table 3.
Relationship between circRNAs level and clinicopathologic characteristics in PCa
| circRNA name | CircBase ID | Host gene | Cutoff value | Internal reference | Dysregulation | Number of patients |
|---|---|---|---|---|---|---|
| circ_SLC19A1 | hsa_circ_0062019 | SLC19A1 | – | 18S rRNA | upregulated | 173 |
| circ_0057558 | hsa_circ_0057558 | SLC19A1 | – | 18S rRNA | upregulated | 173 |
| circAR3 | – | AR | – | GAPDH | upregulated | 91 |
| circAMOTL1L | hsa_circ_000,350 | PCHAD8 | – | GAPDH | Downregulated | 97 |
| circFOXO3 | hsa_circ_0006404 | FOXO3 | MEL | β-actin | upregulated | 53 |
| circABCC4 | hsa_circ_0030586 | ABCC4 | – | GAPDH & U6 | upregulated | 47 |
| circ_ITCH | – | ITCH | MEL | GAPDH & U6 | downregulated | 52 |
| circ-MTO1 | hsa_circ_0076979 | MTO1 | MEL | GAPDH | downregulated | 298 |
| hsa_circ_0001206 | hsa_circ_0001206 | CRKL | – | β-actin | downregulated | 50 |
| hsa_circ_0009061 | hsa_circ_0009061 | KDM1A | – | β-actin | downregulated | 50 |
| circRNA17 | hsa_circ_0001427 | PDLIM5 | – | GAPDH | downregulated | 39 |
| circHIPK3 | hsa_circ_0000284 | HIPK3 | – | GAPDH or U6 | upregulated | 26 |
| circ_ITCH | – | ITCH | MEL | GAPDH | downregulated | 324 |
| circ_0088233 | hsa_circ_0088233 | PAPPA | – | GAPDH | upregulated | 46 |
| circMBOAT2 | hsa_circ_0007334 | MBOAT2 | – | GAPDH | upregulated | 112 |
| circ-0016068 | hsa_circ_0016068 | BTG2 | MEL | GAPDH | upregulated | 42 |
| circFMN2 | hsa_circ_0005100 | FMN2 | MEL | 18S rRNA | upregulated | 88 |
| circ_HIPK3 | – | HIPK3 | – | – | upregulated | 45 |
| hsa_circ_0007494 | hsa_circ_0007494 | ROCK2 | – | GAPDH | downregulated | 49 |
| circ-LARP4 | – | LARP4 | – | GAPDH | downregulated | 55 |
| hsa_circ_0000735 | hsa_circ_0000735 | P2RX1 | MEL | GAPDH | upregulated | 50 |
| Age | Tumor size | Gleason score | PSA | T stage | LNM | Number of tumors | DM | Invasion | Surgical margin | DFS | OS | Reference | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | – | yes | yes | – | – | – | – | yes | – | – | – | Xia et al.59 | 2018 |
| No | – | yes | no | – | – | – | – | no | – | – | – | Xia et al.59 | 2018 |
| – | – | yes | no | – | yes | – | – | no | – | – | – | Luo et al.169 | 2019 |
| No | – | yes | yes | – | – | – | – | – | – | – | – | Yang et al.65 | 2019 |
| No | – | yes | no | – | – | – | – | – | – | – | – | Kong et al.86 | 2020 |
| No | – | – | – | yes | yes | – | yes | – | – | – | yes | Huang et al.75 | 2019 |
| No | – | yes | yes | yes | no | no | – | – | – | – | yes | Wang et al.97 | 2019 |
| No | – | no | no | yes | yes | – | – | – | no | yes | yes | Hu et al.104 | 2020 |
| No | – | yes | no | yes | no | – | – | – | – | – | – | Song et al.66 | 2019 |
| No | – | no | no | yes | no | – | – | – | – | – | – | Song et al.66 | 2019 |
| – | – | yes | – | – | – | – | – | – | – | – | – | Wu et al.94 | 2019 |
| – | – | – | – | yes | – | – | – | – | – | – | – | Chen et al.78 | 2019 |
| No | – | no | no | yes | yes | – | – | – | yes | yes | yes | Huang et al.170 | 2019 |
| No | – | – | – | yes | – | – | – | – | – | – | – | Deng et al.63 | 2020 |
| No | – | yes | no | yes | no | – | – | – | – | yes | – | Shi et al.85 | 2020 |
| No | – | yes | – | yes | yes | – | – | – | – | – | yes | Li et al.64 | 2020 |
| No | – | – | – | yes | yes | – | yes | – | – | – | – | Shang et al.67 | 2020 |
| No | – | yes | – | – | no | – | no | – | – | – | – | Liu et al.90 | 2020 |
| No | yes | no | – | yes | no | – | yes | – | – | – | – | Zhang et al.101 | 2020 |
| – | – | – | – | – | – | – | – | – | – | – | yes | Weng et al.105 | 2020 |
| – | – | – | – | – | – | – | – | – | – | – | yes | Gao et al.82 | 2020 |
MEL, median expression level.